Medinice Sa · GPW:ICE
Medinice Sa — Investor Presentation (April 2026)
28 slides from Medinice Sa's investor presentation, April 2026
Slide 1: Advancing Patients’ Care
Advancing Patients’ Care PacePress | CoolCryo | MiniMax | AtriClamp Corporate presentation April 2026 © 2026 Medinice S.A. All rights reserved.
Slide 2: Mission
Mission We develop advanced solutions to support patients with cardiovascular diseases LEGAL NOTICE This document has been prepared for information purposes only. It does not constitute an advertisement or offer of securities in public trading. It uses sources of information that Medinice S.A. consi
Slide 3: Founders
Founders MEDINICE S.A. Founded in 2012 by renowned medical specialists and an experienced entrepreneur. Develops, creates, and commercializes advanced technologies for the treatment of cardiovascular diseases. Listed on the Warsaw Stock Exchange since 2018. Holds ISO 13485. Sanjeev Choudhary Prof. P
Slide 4: About Company
About Company 17 PLN obtained from patents and 60+ milions grants applications 67 PLN obtained from the implemented 4 milions issue of shares projects 22% 14% 64% 568 PLN value of projects* founders TFI PZU others milions * In February 2026, Trigon DM prepared a project valuation of PLN 568 million.
Slide 5: Management Team
Management Team Sanjeev Choudhary Co-founder Grzegorz Wróblewski, PhD President of the Management Board (CEO) Chief Technology Officer (CTO) Over 25 years of professional experience in Over 15 years of experience in Research & mergers and acquisitions (M&A), business scaling, Development (R&D) and s
Slide 6: Scientific Board
Scientific Board CARDIAC SURGERY ELECTRO PHISIOLOGY Prof. Piotr Prof. Valavanur Prof. Paul Prof. Pawel Prof. Michael Prof. Adam Suwalski MD Subramanian Gründeman Balsam Glikson Budzikowski MD, PhD MD, PhD MD, PhD MD, PhD MD, PhD Director of National Medical Institute of MIA in Poland. Head of Lenox
Slide 7: Pipeline of wide range innovative medical devices
Pipeline of wide range innovative medical devices AtriClamp MiniMax® CoolCryo® PacePress® epicardial RF ablation catheter quick & powerful prevention of LAAO device offering 3D mapping and epi- & endocardial hematoma after cooling cryoablation CIED implants PROTOTYPING PRECLINICAL READY TO-GO-TO REA
Slide 8: Project Status 2026
Project Status 2026 Project Phase Regulatory Status Commercialization ® MDR - recruitment completed CoolCryo in clinical trial (Q4'25) FDA 510(k) Clearance Received Commercial readiness ® MDR - completion of clinical trial MDR - CE audit (Q2'26) Commercial readiness PacePress and positive report (Q3
Slide 9: Cardiovascular Diseases
Cardiovascular Diseases 60 mln people worldwide suffer from arrhythmia Arrhythmia ranks among the most prevalent heart conditions. It can result in circulatory failure and strokes. The preferred treatment approach is ablation. Currently, ablation treatments include: • Cryoablation (CoolCryo®) – free
Slide 10: PacePress®
PacePress® Smart Pressure. Confident Recovery. © 2026 Medinice S.A. All rights reserved.
Slide 11: PACEPRESS®
PACEPRESS® Safer and faster recovery after implantations of Cardiac Implantable Electronic Devices (CIED) PacePress is pneumatic therapeutic medical device designed to minimize the risk of complications after CIED implantations, while ensuring patient comfort, mobility and recovery. Key features • R
Slide 12: CIED Postoperative Complications
CIED Postoperative Complications 1.5 million procedures performed annually worldwide CIED About 60% of patients undergoing CIED implantation implantation procedures are at risk of postoperative complications. site Approximately 10% of CIED procedures result in chest cavity haematomas, potentially le
Slide 13: CIED Market – PacePress®
CIED Market – PacePress® Europe USA India (SAARC) Number of CIED procedures 700K 600K 60K •According to the American Heart Association, there are •Complications in the form of hematoma approximately 6.5 million people in the United States double the length of hospital stay; therefore, eligible for p
Slide 14: CoolCryo®
CoolCryo® © 2026 Medinice S.A. All rights reserved.
Slide 15: CoolCryo®
CoolCryo® Faster and more efficient cardiac cryoablation system The CoolCryo® system is designed for the cryosurgical treatment of arrhythmic cardiac tissue ablation by freezing target tissues, inducing an inflammatory response (cryonecrosis) that blocks the electrical conduction pathway. Using liqu
Slide 16: 510k Review – Procedure After Submission of the Application
510k Review – Procedure After Submission of the Application Day Day Day Day 1 7 15 60 Submission Acknowledgement Letter Acceptance Review Substantive Review Decision Letter The FDA receives The FDA sends a The lead reviewer checks The application undergoes The FDA informs about the our application c
Slide 17: MiniMax®
MiniMax® © 2026 Medinice S.A. All rights reserved.
Slide 18: MINIMAX®
MINIMAX® Versatile RF ablation catheter offering 3D mapping and cooling MiniMax® is a steerable, minimally invasive 2-in-1 catheter developed for the treatment of cardiac arrhythmias during RF ablation procedure. It combines ablation and 3D mapping functions to reduce both the risk and duration of t
Slide 19: Cryoablation and Radiofrequency Ablation Market - CoolCryo® & MiniMax®
Cryoablation and Radiofrequency Ablation Market - CoolCryo® & MiniMax® Size and growth of the cardiac ablation market: •The cardiac ablation market was valued at USD 3.5 billion in 2022 and is projected to grow at a CAGR of 13.5% over the next decade. •The valuation of the surgical cardiac ablation
Slide 20: AtriClamp
AtriClamp Stroke prevention in a simple step. © 2026 Medinice S.A. All rights reserved.
Slide 21: Stroke Prevalence Increasing Across the World
Stroke Prevalence Increasing Across the World Arrhythmia and Atrial fibrillation (AF): 60 million people with arrythmia globally, approx. 5x higher risk of stroke. Stroke Blood clots are created in the LAA Stroke incidence: 15+ million new cases per year worldwide. Top 3 cause of all deaths. Ineffic
Slide 22: LAAC Provides Signigicant Stroke Reduction
LAAC Provides Signigicant Stroke Reduction Surgical closure of the left atrial appendage Eliminates the primary source of clot formation in atrial fibrillation. LAAC procedure concomitant to cardiac surgery Effectively reduces the risk of ischemic stroke by over 90%. One-time procedure without lifel
Slide 23: Core Competitive Avantages
Core Competitive Avantages © 2026 Medinice S.A. All rights reserved.
Slide 24: Unsaturated Marked with Strong Growth Dynamics
Unsaturated Marked with Strong Growth Dynamics Global Market of LAAC Devices (USD Billion) 1. Growing population of patients with arrhythmia More than 60 million patients with arrhythmia worldwide; the prevalence of atrial fibrillation (AF) is increasing at a very rapid pace 2. Guideline-Driven Adop
Slide 25: Strategic Acquirers Have Paid $300M–$400M+ for LAA Systems
Strategic Acquirers Have Paid $300M–$400M+ for LAA Systems Laminar (2023) WATCHMAN (2011) SentreHEART (2019) $400 M + milestones $375 M $300 M Penditure (2023) Coherex Medical (2015) Not Disclosed Not Disclosed LAAC is a proven acquisition category for strategic medtech buyers.
Slide 26: Cardiac Market
Cardiac Market LAAO market 300 mln USD $2 B market size AtriClamp acquisition of SentreHEART by AtriCure in 2019 RF Ablation market 125 mln USD 1 M+ procedures annually MiniMax® w 2023 MACOM acquisition $5.5 B market size of Wolfspeed RF portfolio Cryoablation market $800 M market size CoolCryo® 150
Slide 27: Summary
Summary Repeatable revenue model Growing demand An experienced team •Growing demand for minimally •Scientific Council composed of world-renowned invasive technologies scientists and inventors •Ageing population •Experienced management and project teams Competitive advantages Large and healthy target
Slide 28: Thank you
Mh e ® CAIN |\C/e v of @ \ \ Thank you www.medinice.pl